Frequency and spectrum of PIK3CA somatic mutations in breast cancer

PURPOSE: The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay detects most PIK3CA mutations...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Breast Cancer Res
Autori principali: Martínez-Sáez, Olga, Chic, Nuria, Pascual, Tomás, Adamo, Barbara, Vidal, Maria, González-Farré, Blanca, Sanfeliu, Esther, Schettini, Francesco, Conte, Benedetta, Brasó-Maristany, Fara, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Ana Belén, Martinez, Antonio, Muñoz, Montserrat, Prat, Aleix
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7222307/
https://ncbi.nlm.nih.gov/pubmed/32404150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01284-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi